The role of p-Stat3 Y705 immunohistochemistry in glioblastoma prognosis
Diagnostic Pathology, 2019•Springer
Background In spite of the multimodal treatment used today, glioblastoma is still the most
aggressive and lethal cerebral tumour. To increase survival in these patients, novel
therapeutic targets must be discovered. Signal transducer and activator of transcription 3
(Stat3), a transcription factor that controls normal cell differentiation and survival is also
involved in neoplastic celltransformation. In this study we evaluated the
immunohistochemical expression of pY705-Stat3 in patients with primary glioblastoma and …
aggressive and lethal cerebral tumour. To increase survival in these patients, novel
therapeutic targets must be discovered. Signal transducer and activator of transcription 3
(Stat3), a transcription factor that controls normal cell differentiation and survival is also
involved in neoplastic celltransformation. In this study we evaluated the
immunohistochemical expression of pY705-Stat3 in patients with primary glioblastoma and …
Background
In spite of the multimodal treatment used today, glioblastoma is still the most aggressive and lethal cerebral tumour. To increase survival in these patients, novel therapeutic targets must be discovered. Signal transducer and activator of transcription 3 (Stat3), a transcription factor that controls normal cell differentiation and survival is also involved in neoplastic celltransformation. In this study we evaluated the immunohistochemical expression of pY705-Stat3 in patients with primary glioblastoma and determined its prognostic role by correlating it with survival.
Methods
This retrospective study included 94 patients diagnosed with glioblastoma. We determined the localization, number of positive cells, and marker intensity for pY705-Stat3 in these patients with the use of immunohistochemistry. The prognostic role was determined by correlating pY705-Stat3 expression on formalin-fixed paraffin-embedded tumour tissues with the patient’s survival in univariate and multivariate COX regressions.
Results
We found a statistically significant difference in survival between the patients with more than 20% pY705-Stat3 positive cells and those with less than 20% pY705-Stat3 positive cells (8.9 months median survival versus 13.7 months medial survival, p < 0.001). On multivariate analyses with the COX proportional hazards regression model including pY705-Stat3 expression, age and relapse status, pY705-Stat3 status was an independent prognostic factor in glioblastoma (P < 0.001).
Conclusion
The results obtained show that the immunohistochemical expression of pY705-Stat3 correlates with survival in glioblastoma. This study identifies Stat3 as a possible target for existing or new developed Stat3 inhibitors.
Springer
以上显示的是最相近的搜索结果。 查看全部搜索结果